MedTrace Logo

Dysport Dose-Ranging Treatment of Platysmal Bands

NCT04886167 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-12

No results posted yet for this study

Summary

This is a double-blinded, dose-ranging study in the US to assess the efficacy, safety, and duration of response of abobotulinumtoxinA for the treatment of moderate to severe platysmal bands.

Conditions

  • Platysma Bands

Interventions

DRUG

AbobotulinumtoxinA

Injection of platysmal bands.

Sponsors & Collaborators

  • Galderma R&D

    collaborator INDUSTRY

  • Clinical Testing of Beverly Hills

    lead OTHER

Principal Investigators

  • John Joseph, MD · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-30
Primary Completion
2022-11-01
Completion
2022-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04886167 on ClinicalTrials.gov